Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Scarpa Mario; Kapoor Shivani; Perrotti Danilo; Baer Maria R.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

【24h】

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

机译：并发FLT3抑制剂和PP2A活化药物治疗在急性髓性白血病细胞中诱导协同细胞毒性，通过PIM-1和C-MYC的蛋白酶体降解通过PIM-1和C-Myc的抗体重复

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Scarpa Mario; Kapoor Shivani; Perrotti Danilo; Baer Maria R.;
展开▼
作者单位

Univ Maryland Greenebaum Comprehens Canc Ctr Baltimore MD 21201 USA;

Univ Maryland Greenebaum Comprehens Canc Ctr Baltimore MD 21201 USA;

Greenebaum Canc Ctr Baltimore MD USA;

Univ Maryland Greenebaum Comprehens Canc Ctr Baltimore MD 21201 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
专利

1. Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc [J] . Scarpa Mario, Kapoor Shivani, Perrotti Danilo, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：并发FLT3抑制剂和PP2A活化药物治疗在急性髓性白血病细胞中诱导协同细胞毒性，通过PIM-1和C-MYC的蛋白酶体降解通过PIM-1和C-Myc的抗体重复
2. Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial [J] . Cortes Jorge E., Khaled Samer K., Martinelli Giovanni, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单药剂Quizartinib（Q），有效和选择性FLT3抑制剂（FLT3I），患者（PTS）的疗效和安全性，具有FLT3 - 内部串联复制（FLT3-ITD） - 矫正复发/难以（R / R）急性髓样 Leukemia（AML）注册了全球第3阶段，随机控制量子-R试验
3. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD) [J] . Lu Jeng-Wei, Wang An-Ni, Liao Heng-An, Cancer letters . 2016,第2期

机译：卡博替尼在具有FLT3内部串联复制（FLT3-ITD）的急性髓样白血病细胞中具有选择性细胞毒性
4. Tandem mass spectrometry characterizes the related substances of second generation FLT3 inhibitor Quizartinib, anti cancer compound for myeloid leukemia [C] . Saravanan Subramaniyan, Arvind Thyagarajan, Rampriya Uthayakumar, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：串联质谱表征第二代FLT3抑制剂Quizartinib的相关物质，用于髓性白血病的抗癌化合物
5. Comparison of FLT3 Inhibitors with the Standard Treatment for FLT3-ITD Mutated Acute Myeloid Leukemia [D] . Argetsinger, Stephanie. 2018

机译：FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
6. Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication [O] . Karthika Natarajan, Yingqiu Xie, Mehmet Burcu, -1

机译：Pim-1激酶磷酸化并稳定130 kDa FLT3并通过FLT3内部串联复制促进急性髓样白血病的异常STAT5信号传导。
7. Combining the FLT3 Inhibitor PKC412 and the Triterpenoid CDDO-Me Synergistically Induces Apoptosis in Acute Myeloid Leukemia with the Internal Tandem Duplication Mutation [O] . Rehan Ahmad, Suiyang Liu, Ellen Weisberg, 2010

机译：结合FLT3抑制剂PKC412和三萜CDDO-ME协同诱导急性髓性白血病中的细胞凋亡与内部串联重复突变

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

著录项

相似文献

相关主题

期刊订阅